In connection with the reduction in workforce, Bellerophon Therapeutics, Inc. intends to enter into separation and/or transition agreements with each of Peter Fernandes, the Company’s Chief Executive Officer, which are expected to provide for their separation of employment, effective July 15, 2023 or any such later date as agreed upon by the Company and such individual.